TY - JOUR
T1 - Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer
AU - Pällmann, Nora
AU - Livgård, Marte
AU - Tesikova, Martina
AU - Zeynep Nenseth, Hatice
AU - Akkus, Erman
AU - Sikkeland, Jørgen
AU - Jin, Yang
AU - Koc, Dogukan
AU - Kuzu, Omer Faruk
AU - Pradhan, Manohar
AU - Danielsen, Håvard E.
AU - Kahraman, Nermin
AU - Mokhlis, Hamada M.
AU - Ozpolat, Bulent
AU - Banerjee, Partha P.
AU - Uren, Aykut
AU - Fazli, Ladan
AU - Rennie, Paul S.
AU - Jin, Yang
AU - Saatcioglu, Fahri
N1 - Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/8/29
Y1 - 2019/8/29
N2 - Cancer cells exploit many of the cellular adaptive responses to support their survival needs. One such critical pathway in eukaryotic cells is the unfolded protein response (UPR) that is important in normal physiology as well as disease states, including cancer. Since UPR can serve as a lever between survival and death, regulated control of its activity is critical for tumor formation and growth although the underlying mechanisms are poorly understood. Here we show that one of the main transcriptional effectors of UPR, activating transcription factor 4 (ATF4), is essential for prostate cancer (PCa) growth and survival. Using systemic unbiased gene expression and proteomic analyses, we identified a novel direct ATF4 target gene, family with sequence similarity 129 member A (FAM129A), which is critical in mediating ATF4 effects on prostate tumorigenesis. Interestingly, FAM129A regulated both PERK and eIF2α in a feedback loop that differentially channeled the UPR output. ATF4 and FAM129A protein expression is increased in patient PCa samples compared with benign prostate. Importantly, in vivo therapeutic silencing of ATF4-FAM129A axis profoundly inhibited tumor growth in a preclinical PCa model. These data support that one of the canonical UPR branches, through ATF4 and its target gene FAM129A, is required for PCa growth and thus may serve as a novel therapeutic target.
AB - Cancer cells exploit many of the cellular adaptive responses to support their survival needs. One such critical pathway in eukaryotic cells is the unfolded protein response (UPR) that is important in normal physiology as well as disease states, including cancer. Since UPR can serve as a lever between survival and death, regulated control of its activity is critical for tumor formation and growth although the underlying mechanisms are poorly understood. Here we show that one of the main transcriptional effectors of UPR, activating transcription factor 4 (ATF4), is essential for prostate cancer (PCa) growth and survival. Using systemic unbiased gene expression and proteomic analyses, we identified a novel direct ATF4 target gene, family with sequence similarity 129 member A (FAM129A), which is critical in mediating ATF4 effects on prostate tumorigenesis. Interestingly, FAM129A regulated both PERK and eIF2α in a feedback loop that differentially channeled the UPR output. ATF4 and FAM129A protein expression is increased in patient PCa samples compared with benign prostate. Importantly, in vivo therapeutic silencing of ATF4-FAM129A axis profoundly inhibited tumor growth in a preclinical PCa model. These data support that one of the canonical UPR branches, through ATF4 and its target gene FAM129A, is required for PCa growth and thus may serve as a novel therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=85069054087&partnerID=8YFLogxK
U2 - 10.1038/s41388-019-0879-2
DO - 10.1038/s41388-019-0879-2
M3 - Article
C2 - 31312022
AN - SCOPUS:85069054087
SN - 0950-9232
VL - 38
SP - 6301
EP - 6318
JO - Oncogene
JF - Oncogene
IS - 35
ER -